Your browser doesn't support javascript.
loading
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Brasó-Maristany, Fara; Griguolo, Gaia; Chic, Nuria; Pascual, Tomás; Paré, Laia; Maues, Julia; Galván, Patricia; Dieci, Maria Vittoria; Miglietta, Federica; Giarratano, Tommaso; Martínez-Sáez, Olga; Marín-Aguilera, Mercedes; Schettini, Francesco; Conte, Benedetta; Angelats, Laura; Vidal, Maria; Adamo, Barbara; Muñoz, Montserrat; Sanfeliu, Esther; González, Blanca; Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Conte, PierFranco; Prat, Aleix; Guarneri, Valentina.
Afiliação
  • Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Chic N; Division of Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Pascual T; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Paré L; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Maues J; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Galván P; SOLTI Cooperative Group, Barcelona, Spain.
  • Dieci MV; Reveal Genomics, Barcelona, Spain.
  • Miglietta F; GRASP, Baltimore, MD, USA.
  • Giarratano T; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Martínez-Sáez O; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Marín-Aguilera M; Division of Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Schettini F; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Conte B; Division of Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Angelats L; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
  • Vidal M; Division of Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Adamo B; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Muñoz M; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Sanfeliu E; Department of Medicine, University of Barcelona, Barcelona, Spain.
  • González B; Reveal Genomics, Barcelona, Spain.
  • Vivancos A; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Villagrasa P; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Parker JS; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Perou CM; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Conte P; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Prat A; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain.
  • Guarneri V; Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
J Natl Cancer Inst ; 115(3): 332-336, 2023 03 09.
Article em En | MEDLINE | ID: mdl-36576009
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P < .001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P = .002) and overall survival (OS; P = .02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P = .04) and immunoglobulin signature (P = .04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Maitansina Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Maitansina Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article